SAFC completes Jerusalem fermentation plant expansion
This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.
In an exclusive video interview, SAFC president Gilles Cottier and VP of contract manufacturing services Mark Cassidy told in-Pharmatechnologist that growing industry demand for high potency active pharmaceutical ingredients (APIs) was the key driver for the investment.
Cottier also explained that the addition of such capability is an important part of differentiating SAFC's offering in the increasingly competitive global contract manufacturing sector
The 50,000 expansion includes capacity for bulk drugs, secondary metabolites, cytotoxins and a range of large molecules proteins. SAFC has also installed additional
